Trial Profile
An Open Label Exploratory Study to Investigate the Safety and Effects of NPL-2009 ( 50 mg - 150 mg Single Dose) on Prepulse Inhibition Tests and Continuous Performance Tasks, in Adults With Fragile X Syndrome
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 May 2012
Price :
$35
*
At a glance
- Drugs Fenobam (Primary)
- Indications Fragile X syndrome
- Focus Adverse reactions; Pharmacodynamics
- 03 May 2012 New trial record